查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2153423

電腦輔助藥物發現（CAAD）全球市場規模、佔有率、趨勢和成長分析報告（2026-2034）

Global Computer-Aided Drug Discovery Market Size, Share, Trends & Growth Analysis Report 2026-2034
出版日期: | 出版商: Value Market Research | 英文 197 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

全球電腦輔助藥物發現（CAAD）市場預計將從2025年的52億美元成長至2034年的146.2億美元，2026年至2034年的複合年成長率（CAGR）為12.17%。隨著製藥和生物技術公司擴大利用計算技術來加速藥物發現研究並提高早期開發效率，該市場正在不斷擴張。電腦輔助藥物發現利用分子建模、虛擬篩檢、分子對接和計算化學等技術來識別和評估有前景的候選藥物。這些方法使研究人員能夠在對選定的候選藥物進行實驗室測試之前，研究化合物與生物標靶之間的相互作用。對更高效藥物發現的需求不斷成長，加上計算能力的提升和生物數據可用性的提高，正在推動計算工具在整體的應用。

市場成長的驅動力來自不斷增加的藥物研發投入、人工智慧的進步以及基因組學、蛋白質組學和結構生物學數據的日益豐富。機器學習模型有助於識別有前景的化合物、預測分子特性，並優先篩選候選化合物進行實驗檢驗。雲端運算和專用軟體平台使研究機構更容易取得運算資源。製藥公司也正與技術提供商和生物技術公司合作，將計算預測與實驗室實驗結合。這些進步使研究人員能夠揭示複雜的生物標的，提高篩檢效率，並探索治療選擇有限的疾病的潛在療法。

該市場的未來前景取決於預測準確性、數據品質、計算模型改進以及與實驗研究的融合等方面的進步。人工智慧有望在標靶識別、分子設計、毒性預測和候選化合物最佳化等方面發揮越來越重要的作用。生成模型有助於研究人員探索具有理想特性的新型分子結構，而改進的模擬技術則可能提供對生物相互作用更深入的見解。然而，資料集不完整、模型可靠性、實驗檢驗以及監管要求等方面的限制仍將是需要重點考慮的因素。將計算方法與實驗室研究結果和臨床研究相結合，對於將有前景的發現轉化為安全有效的藥物至關重要。

我們的報告經過精心撰寫，旨在提供涵蓋廣泛行業和市場的全面且切實可行的洞察。每份報告都包含幾個關鍵組成部分，旨在幫助您全面了解市場環境：

市場概覽：本節對市場進行了清晰的說明，包括關鍵定義、分類以及當前行業格局的概述。

市場動態：對影響市場成長的主要促進因素、阻礙因素、機會和挑戰進行詳細評估。這包括技術發展、法律規範和不斷變化的行業趨勢等因素。

市場區隔分析：本部分根據產品類型、應用、最終用戶和地區將市場系統性地分類為若干關鍵細分市場。本部分揭示了每個細分市場的表現、成長潛力和市場貢獻。

競爭格局：我們對主要市場參與企業進行了詳細評估，包括其市場定位、產品系列、策略舉措和財務表現。這有助於深入了解競爭趨勢和主要參與者所採取的策略。

市場預測：本部分提供基於數據的市場規模和成長模式預測，預測期為特定時期。它綜合考慮了歷史趨勢、當前市場狀況和定量分析，以識別未來預期趨勢。

區域分析：這包括對主要地理區域的市場表現進行全面檢驗，確定高成長領域和區域趨勢，以更深入地了解每個區域特有的市場機會。

新趨勢與新機會：識別關鍵市場趨勢、技術進步和新興投資機會。本部分重點在於潛在成長領域和未來產業趨勢。

客製化選項：我們提供靈活的報告客製化服務，以滿足您的特定需求。這包括額外的細分、國家/地區分析、競爭對手分析、客製化資料點或針對特定細分市場的洞察，以更好地支援您的策略決策。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

  • 市場譜系展望
  • 滲透率和成長前景分析
  • 價值鏈分析
  • 法律規範
    • 標準與合規性
    • 監管影響分析
  • 市場動態
    • 市場促進因素
    • 市場限制因素
    • 市場機遇
    • 市場挑戰
  • 波特五力分析
  • PESTLE分析

第4章：全球電腦輔助藥物發現（CAAD）市場：按類型分類

  • 市場分析、洞察與預測
  • 基於結構的藥物發現
  • 基於配體的藥物發現
  • 基於數組的方法

第5章：全球電腦輔助藥物發現（CAAD）市場：依治療領域分類

  • 市場分析、洞察與預測
  • 腫瘤學
  • 神經病學
  • 心血管疾病
  • 呼吸系統疾病
  • 糖尿病
  • 其他

第6章：全球電腦輔助藥物發現（CAAD）市場：依最終使用者分類

  • 市場分析、洞察與預測
  • 製藥公司
  • 生技公司
  • 研究所

第7章 全球電腦輔助藥物發現（CAAD）市場：按地區分類

  • 區域分析
  • 北美市場分析、洞察與預測
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲市場分析、洞察與預測
    • 英國
    • 法國
    • 德國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他歐洲國家
  • 亞太市場分析、洞察與預測
    • 中國
    • 日本
    • 韓國
    • 印度
    • 澳洲
    • 東南亞
    • 其他亞太國家
  • 拉丁美洲市場分析、洞察與預測
    • 巴西
    • 阿根廷
    • 秘魯
    • 智利
    • 其他拉丁美洲國家
  • 中東和非洲市場分析、洞察與預測
    • 沙烏地阿拉伯
    • UAE
    • 以色列
    • 南非
    • 其他中東和非洲國家

第8章 競爭情勢

  • 最新趨勢
  • 公司分類
  • 供應鏈和銷售管道合作夥伴（根據現有資訊）
  • 市場佔有率和市場定位分析（基於現有資訊）
  • 供應商情況（基於現有資訊）
  • 策略規劃

第9章：公司簡介

  • 主要公司的市佔率分析
  • 公司簡介
    • Schrodinger
    • Exscientia
    • Insilico Medicine
    • BenevolentAI
    • Recursion Pharmaceuticals
    • Atomwise
    • XtalPi
    • Relay Therapeutics
    • Genesis Therapeutics
    • Nimbus Therapeutics
    • Deep Genomics
    • Verge Genomics
    • Owkin
    • Valence Discovery
    • Generate Biomedicines
    • Iktos
    • Evotec
    • Cyclica
    • Numerate
    • Absci
簡介目錄
Product Code: VMR11218710

The global computer-aided drug discovery market size is expected to reach USD 14.62 Billion in 2034 from USD 5.20 Billion in 2025, growing at a CAGR of 12.17% during 2026-2034.This market is expanding as pharmaceutical and biotechnology companies increasingly use computational technologies to accelerate drug research and improve the efficiency of early-stage development. Computer-aided drug discovery uses methods such as molecular modeling, virtual screening, molecular docking, and computational chemistry to identify and evaluate potential drug candidates. These approaches can help researchers investigate interactions between compounds and biological targets before advancing selected candidates to laboratory testing. Growing demand for more efficient drug development, combined with advances in computing power and biological data availability, is encouraging the adoption of computational tools across pharmaceutical research.

Market growth is driven by increasing pharmaceutical research expenditure, advances in artificial intelligence, and the growing availability of genomic, proteomic, and structural biology data. Machine learning models can help identify promising compounds, predict molecular properties, and prioritize candidates for experimental validation. Cloud computing and specialized software platforms are making computational resources more accessible to research organizations. Pharmaceutical companies are also collaborating with technology providers and biotechnology firms to combine computational predictions with laboratory experiments. These developments are helping researchers investigate complex biological targets, improve screening efficiency, and explore potential treatments for diseases with limited therapeutic options.

The future prospects of this market will depend on improvements in predictive accuracy, data quality, computational models, and integration with experimental research. Artificial intelligence may increasingly support target identification, molecular design, toxicity prediction, and optimization of candidate compounds. Generative models could help researchers explore new molecular structures with desired characteristics, while improved simulation methods may provide deeper insights into biological interactions. However, limitations involving incomplete datasets, model reliability, experimental validation, and regulatory expectations will remain important considerations. Combining computational approaches with laboratory evidence and clinical research will be essential for translating promising discoveries into safe and effective medicines.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Type

  • Structure Based Drug Design
  • Ligand-Based Drug Design
  • Sequence-Based Approaches

By Therapeutic Area

  • Oncology
  • Neurology
  • Cardiovascular Disease
  • Respiratory Disease
  • Diabetes
  • Others

By End User

  • Pharmaceutical Companies
  • Biotechnology Companies
  • Research Laboratories

COMPANIES PROFILED

  • Schrodinger, Exscientia, Insilico Medicine, BenevolentAI, Recursion Pharmaceuticals, Atomwise, XtalPi, Relay Therapeutics, Genesis Therapeutics, Nimbus Therapeutics, Deep Genomics, Verge Genomics, Owkin, Valence Discovery, Generate Biomedicines, Iktos, Evotec, Cyclica, Numerate, Absci

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET: BY TYPE 2022-2034 (USD MN)

  • 4.1. Market Analysis, Insights and Forecast Type
  • 4.2. Structure Based Drug Design Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.3. Ligand-Based Drug Design Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.4. Sequence-Based Approaches Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET: BY THERAPEUTIC AREA 2022-2034 (USD MN)

  • 5.1. Market Analysis, Insights and Forecast Therapeutic Area
  • 5.2. Oncology Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.3. Neurology Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.4. Cardiovascular Disease Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.5. Respiratory Disease Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.6. Diabetes Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.7. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET: BY END USER 2022-2034 (USD MN)

  • 6.1. Market Analysis, Insights and Forecast End User
  • 6.2. Pharmaceutical Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.3. Biotechnology Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.4. Research Laboratories Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET: BY REGION 2022-2034 (USD MN)

  • 7.1. Regional Outlook
  • 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.2.1 By Type
    • 7.2.2 By Therapeutic Area
    • 7.2.3 By End User
    • 7.2.4 United States
    • 7.2.5 Canada
    • 7.2.6 Mexico
  • 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.3.1 By Type
    • 7.3.2 By Therapeutic Area
    • 7.3.3 By End User
    • 7.3.4 United Kingdom
    • 7.3.5 France
    • 7.3.6 Germany
    • 7.3.7 Italy
    • 7.3.8 Spain
    • 7.3.9 Russia
    • 7.3.10 Rest Of Europe
  • 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.4.1 By Type
    • 7.4.2 By Therapeutic Area
    • 7.4.3 By End User
    • 7.4.4 China
    • 7.4.5 Japan
    • 7.4.6 South Korea
    • 7.4.7 India
    • 7.4.8 Australia
    • 7.4.9 South East Asia
    • 7.4.10 Rest Of Asia Pacific
  • 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.5.1 By Type
    • 7.5.2 By Therapeutic Area
    • 7.5.3 By End User
    • 7.5.4 Brazil
    • 7.5.5 Argentina
    • 7.5.6 Peru
    • 7.5.7 Chile
    • 7.5.8 Rest of Latin America
  • 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.6.1 By Type
    • 7.6.2 By Therapeutic Area
    • 7.6.3 By End User
    • 7.6.4 Saudi Arabia
    • 7.6.5 UAE
    • 7.6.6 Israel
    • 7.6.7 South Africa
    • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

  • 8.1. Recent Developments
  • 8.2. Company Categorization
  • 8.3. Supply Chain & Channel Partners (based on availability)
  • 8.4. Market Share & Positioning Analysis (based on availability)
  • 8.5. Vendor Landscape (based on availability)
  • 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL COMPUTER-AIDED DRUG DISCOVERY INDUSTRY

  • 9.1. Top Companies Market Share Analysis
  • 9.2. Company Profiles
    • 9.2.1 Schrodinger
    • 9.2.2 Exscientia
    • 9.2.3 Insilico Medicine
    • 9.2.4 BenevolentAI
    • 9.2.5 Recursion Pharmaceuticals
    • 9.2.6 Atomwise
    • 9.2.7 XtalPi
    • 9.2.8 Relay Therapeutics
    • 9.2.9 Genesis Therapeutics
    • 9.2.10 Nimbus Therapeutics
    • 9.2.11 Deep Genomics
    • 9.2.12 Verge Genomics
    • 9.2.13 Owkin
    • 9.2.14 Valence Discovery
    • 9.2.15 Generate Biomedicines
    • 9.2.16 Iktos
    • 9.2.17 Evotec
    • 9.2.18 Cyclica
    • 9.2.19 Numerate
    • 9.2.20 Absci